Legend Biotech, a subsidiary of GenScript Biotech Corporation, announced that the U.S. Food and Drug Administration (FDA) has authorized its development partner, Janssen Biotech, to commence a Phase 1b/2 clinical trial in patients with relapsed or refractory Multiple Myeloma (MM) to evaluate the safety and efficacy of LCAR-B38M (JNJ-68284528), a Chimeric Antigen Receptor T cell (CAR-T) therapy.    Scheduled to begin enrollment in the second half of 2018, the Phase 1b/2 study (68284528MMY...